Stockholm, 5th December 2022 — Alex Therapeutics and Vicore Pharma today announce the first study…
Continue Reading-
Step Pharma Announces First Patient Dosed with STP938, the World’s Most Advanced CTPS1 Inhibitor, in a Phase 1/2 Trial for T cell and B cell lymphomas
Step Pharma Announces First Patient Dosed with STP938, the World’s Most Advanced CTPS1 Inhibitor, in…
Continue Reading -
Gesynta Pharma prepares Phase II study of GS-248 in endometriosis following ground-breaking data from a preclinical proof-of-concept study
Gesynta Pharma prepares Phase II study of GS-248 in endometriosis following ground-breaking data from a…
Continue Reading -
Alex Therapeutics presents results from digital therapeutic pilot study showing nearly 50% reduction in anxiety
The Digital Therapeutic (DTx) was developed by DTx leader Alex Therapeutics using the proprietary “Alex…
Continue Reading -
Abliva decides on a SEK 200 million financing to fund Phase 2/3 study of KL1333 to interim analysis and bring in new global life science and institutional investors
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG…
Continue Reading -
Gesynta Pharma’s drug candidate GS-248 granted Orphan Drug Designation by the FDA
Gesynta Pharma’s drug candidate GS-248 granted Orphan Drug Designation in US by the FDA for…
Continue Reading -
Alex Therapeutics raises €3.5M in oversubscribed financing round
Alex Therapeutics aspires to become the global go-to partner for pharma, and other life-science companies…
Continue Reading -
TargED Biopharmaceuticals raises EUR 39 Million in Series A financing
TargED Biopharmaceuticals raises EUR 39 Million in Series A financing
Continue Reading -
Ribbon Biolabs raises EUR 18 million in its Series A financing
Ribbon Biolabs Raises EUR 18 Million Series A Financing
Continue Reading